Andrew Gengos
Director of Finance/CFO chez ATHIRA PHARMA, INC.
Fortune : 229 623 $ au 31/03/2024
Profil
Andrew W.
Gengos currently works at Turn Therapeutics(TM), Inc, as Director and Athira Pharma, Inc., as Chief Financial & Business Officer from 2023.
Mr. Gengos also formerly worked at ImmunoCellular Therapeutics Ltd., as President, Chief Executive Officer & Director from 2012 to 2016, Neuraltus Pharmaceuticals, Inc., as President, Chief Executive Officer & Director from 2010 to 2012, Allozyne, Inc., as Director, Amgen, Inc., as Vice President-Strategy & Corporate Development from 2002 to 2010, Chiron Corp., as Vice President-Strategy & Development in 2010, Dynavax Technologies Corp., as Chief Financial & Business Officer, McKinsey & Co., Inc., as Senior Manager-Engagement from 1991 to 1998, Relypsa, Inc., as Vice President-Strategy & Corporate Development in 2010, Cyteir Therapeutics, Inc., as Chief Business Officer from 2020 to 2023, Synlogic, Inc., as COO & Head-Corporate Development from 2017 to 2018, and AOBiome Therapeutics, Inc., as Chief Financial & Business Officer in 2019.
Mr. Gengos received his undergraduate degree from Massachusetts Institute of Technology and Masters Business Admin degree from UCLA Anderson School of Management.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ATHIRA PHARMA, INC.
0,22% | 26/03/2024 | 83 804 ( 0,22% ) | 229 623 $ | 31/03/2024 |
Postes actifs de Andrew Gengos
| Sociétés | Poste | Début |
|---|---|---|
| ATHIRA PHARMA, INC. | Director of Finance/CFO | 18/05/2023 |
Turn Therapeutics(TM), Inc
 Turn Therapeutics(TM), Inc Medical SpecialtiesHealth Technology Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation. | Director/Board Member | - |
Anciens postes connus de Andrew Gengos
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Corporate Officer/Principal | 03/02/2023 |
AOBiome Therapeutics, Inc.
 AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Director of Finance/CFO | 01/12/2019 |
| SYNLOGIC, INC. | Chief Operating Officer | 01/12/2018 |
| EOM PHARMACEUTICALS HOLDINGS, INC. | Chief Executive Officer | 01/12/2016 |
Neuraltus Pharmaceuticals, Inc.
 Neuraltus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuraltus Pharmaceuticals, Inc. develops and commercializes molecule therapeutics. It engages in the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death. The company was founded by Michael McGrath, Edgar G. Engleman, and Ari Azhir in 2004 and is headquartered in San Bruno, CA. | Chief Executive Officer | 01/08/2012 |
Formation de Andrew Gengos
| Massachusetts Institute of Technology | Undergraduate Degree |
| UCLA Anderson School of Management | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| ATHIRA PHARMA, INC. | Health Technology |
| CYTEIR THERAPEUTICS, INC. | Health Technology |
| SYNLOGIC, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Chiron Corp. provides nucleic acid test for blood screening. Its products include tigris system, target capture system, reagent preparation incubator, and many more. The company was founded in 1981 by William J. Rutter, Edward E. Penhoet & Pablo Valenzuela and is headquartered in Emeryville, CA. | Health Technology |
Allozyne, Inc.
 Allozyne, Inc. Medical SpecialtiesHealth Technology Allozyne, Inc. operates as a biotechnology company that develops and manufactures pharmaceutical products. The firm focuses on manufacture of protein therapeutics for the medical need in autoimmune diseases and cancer. The company was founded by David A. Tirrell, Deepshikha Datta, and William A. Goddard, III in March 2004 and is headquartered in Seattle, WA. | Health Technology |
ImmunoCellular Therapeutics Ltd.
 ImmunoCellular Therapeutics Ltd. BiotechnologyHealth Technology ImmunoCellular Therapeutics, Ltd. is a clinical-stage pharmaceutical company, focused on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. The company was founded on March 20, 1987 and is headquartered in Montvale, NJ. | Health Technology |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
Neuraltus Pharmaceuticals, Inc.
Neuraltus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Neuraltus Pharmaceuticals, Inc. develops and commercializes molecule therapeutics. It engages in the development of therapeutics to treat neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Alzheimer's disease as well as inherited metaboloic disorders such as Fabry's disease and Gaucher's disease which also result in neuronal cell death. The company was founded by Michael McGrath, Edgar G. Engleman, and Ari Azhir in 2004 and is headquartered in San Bruno, CA. | Health Technology |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |
Turn Therapeutics(TM), Inc
Turn Therapeutics(TM), Inc Medical SpecialtiesHealth Technology Turn Therapeutics(TM), Inc is a pharmaceutical and medical device organization that aims to reduce the human and economic costs of infection and skin disease. Turn Therapeutics(TM is based in Calabasas, CA. The private company's core mission is to innovate and educate in order to render disease obsolete. The company has multiple, mass market-ready, proprietary assets incorporating advanced delivery and healing technologies, including their FDA cleared product, Hexagen® wound dressing, which is non-irritating, non-cytotoxic, and non-sensitizing, as well as suitable for extended-wear. The company was founded by Bradley Burnam, who has been the CEO since incorporation. | Health Technology |
